CAPN12 Antibody

What is CAPN12 and what cellular functions does it regulate?

CAPN12 (Calpain-12) belongs to the calpain family of calcium-activated neutral cysteine proteinases. It functions as a calcium-regulated non-lysosomal thiol-protease involved in protein degradation, cell migration, and cell cycle regulation . The human CAPN12 gene is identified with NCBI Gene ID 147968 and UniProt ID Q6ZSI9 . While its specific substrates remain under investigation, CAPN12, like other calpains, likely participates in various signaling pathways by cleaving specific protein substrates, thereby modulating their activity, localization, or interactions.

What are the key characteristics of commercially available CAPN12 antibodies?

Based on available information, CAPN12 antibodies typically share these characteristics:

• Host species: Rabbit

• Clonality: Polyclonal

• Species reactivity: Human

• Tested applications: Western Blotting (WB) and ELISA

• Immunogen: Synthesized peptides derived from the internal region of human CAPN12

• Form: Liquid in PBS buffer (without Mg²⁺ and Ca²⁺), pH 7.4, containing 150mM NaCl, 0.02% sodium azide, and 50% glycerol

• Purification method: Affinity-purified from rabbit antiserum using epitope-specific immunogen

• Storage recommendations: Aliquot and store at -20°C, avoiding repeated freeze/thaw cycles

What are the recommended dilutions for CAPN12 antibodies in different applications?

The optimal working dilutions for CAPN12 antibodies vary by application:

• Western Blotting (WB): 1:500 to 1:3000

• ELISA: Approximately 1:5000

Manufacturers consistently recommend that researchers determine the optimal dilutions for their specific experimental systems . These dilutions have been validated using various cell lines, including 293 (HEK293), NIH-3T3, A549, and K562 cells .

What controls should be included when using CAPN12 antibodies in Western blotting?

When designing experiments with CAPN12 antibodies, include these essential controls:

• Positive controls:

  • Cell lines known to express CAPN12 (e.g., HEK293, NIH-3T3, A549, K562)

  • Recombinant CAPN12 protein (available as Myc-DYKDDDDK tagged protein)

• Negative controls:

  • Cell lines with low or no CAPN12 expression

  • CAPN12 knockdown or knockout samples (if available)

• Technical controls:

  • Loading control (e.g., β-actin, GAPDH) to normalize for total protein

  • Secondary antibody-only control to assess non-specific binding

  • Blocking peptide competition using the immunizing peptide

• Experimental controls:

  • Untreated samples as baseline

  • Vehicle controls for treatment experiments

These controls help validate antibody specificity, confirm detected protein identity, and ensure that observed changes in CAPN12 levels are due to experimental conditions rather than technical variations.

How should samples be prepared for optimal detection of CAPN12?

While specific guidance for CAPN12 is limited in available data, standard protocols for protease detection can be adapted:

• Cell/tissue lysis considerations:

  • Use buffers containing protease inhibitors to prevent degradation

  • Consider calcium chelators (e.g., EGTA) if studying inactive CAPN12

  • Maintain consistent lysis conditions across experimental groups

• Sample preparation:

  • Keep samples cold throughout preparation

  • Quantify protein concentration using reliable methods (e.g., BCA assay)

  • For Western blotting, denature samples in reducing buffer at 95°C for 5 minutes

• Storage considerations:

  • Avoid repeated freeze-thaw cycles

  • Aliquot lysates before freezing

  • Store at -80°C for long-term preservation of protein integrity

Since CAPN12 is calcium-activated, researchers should consider how calcium levels during sample preparation might affect the protein's conformation and antibody recognition.

How can researchers validate the specificity of a CAPN12 antibody?

Antibody validation is crucial for reliable research outcomes. For CAPN12 antibodies, employ these approaches:

• Genetic validation:

  • Compare antibody signal between wild-type and CAPN12 knockout/knockdown samples

  • A specific antibody should show reduced or absent signal in knockout/knockdown samples

• Peptide competition:

  • Pre-incubate antibody with excess immunizing peptide before application

  • Specific binding should be blocked by the competing peptide

• Recombinant protein analysis:

  • Test antibody recognition of recombinant CAPN12 protein

  • Compare with size markers to confirm expected molecular weight

• Multiple antibodies approach:

  • Use different antibodies targeting distinct CAPN12 epitopes

  • Consistent detection patterns suggest specific recognition

These validation approaches provide complementary evidence for antibody specificity and should ideally be combined for comprehensive validation.

How can CAPN12 antibodies be used to study protein-protein interactions?

CAPN12 antibodies enable several approaches to investigate protein interactions:

• Co-immunoprecipitation (Co-IP):

  • Immunoprecipitate CAPN12 from cell lysates using specific antibodies

  • Analyze co-precipitated proteins by Western blotting or mass spectrometry

  • This identifies proteins that interact with CAPN12 in vivo

• Proximity ligation assay (PLA):

  • Combine CAPN12 antibody with antibodies against potential interacting partners

  • PLA signal indicates close proximity (<40 nm) between proteins

  • Useful for visualizing interactions in their cellular context

• Immunofluorescence co-localization:

  • Use CAPN12 antibody alongside antibodies against potential interacting partners

  • Analyze co-localization using confocal microscopy

  • Co-localization suggests potential physical interaction

When designing these experiments, consider the calcium-dependent nature of CAPN12 activation and maintain appropriate calcium concentrations to capture physiologically relevant interactions.

What approaches can be used to investigate CAPN12 activity rather than just expression?

As a protease, CAPN12's functional significance relates to its enzymatic activity. Several methodologies can assess CAPN12 activity:

• Activity-based protein profiling:

  • Use activity-based probes that bind to active cysteine proteases

  • Visualize active CAPN12 in complex samples

  • Compare activity across experimental conditions

• Substrate cleavage assays:

  • Identify or design substrates specific for CAPN12

  • Monitor their cleavage through various detection methods

  • Correlate cleavage with CAPN12 expression levels

• Calcium-dependent activity assays:

  • Perform activity assays with varying calcium concentrations

  • Determine calcium requirements for CAPN12 activation

  • Compare with other calpain family members

These functional assays provide insights beyond expression data and help understand how CAPN12 activity is regulated in physiological and pathological contexts.

How can researchers study post-translational modifications of CAPN12?

Post-translational modifications (PTMs) can significantly impact CAPN12 function and regulation:

• Immunoprecipitation-based approaches:

  • Immunoprecipitate CAPN12 using specific antibodies

  • Analyze by Western blotting with modification-specific antibodies

  • Alternatively, analyze by mass spectrometry for comprehensive PTM profiling

• Phosphorylation analysis:

  • Use phosphatase treatments as controls

  • Compare mobility shifts before and after treatment

  • Employ phospho-specific antibodies if available

• Mass spectrometry-based identification:

  • Analyze purified or immunoprecipitated CAPN12 by LC-MS/MS

  • Search for characteristic mass shifts indicating modifications

  • Quantify modification stoichiometry across conditions

Understanding CAPN12's PTM profile may provide insights into its regulation and function in different cellular contexts.

Why might CAPN12 detection yield inconsistent results?

Several factors can contribute to variability in CAPN12 detection:

• Antibody-related issues:

  • Batch-to-batch variation in polyclonal antibodies

  • Degradation due to improper storage

  • Cross-reactivity with other calpain family members

• Sample preparation variables:

  • Inconsistent protein extraction efficiency

  • Protein degradation during preparation

  • Variable calcium levels affecting CAPN12 conformation

• Technical variables:

  • Inconsistent transfer efficiency in Western blotting

  • Variable blocking efficiency

  • Differences in detection sensitivity

To address these issues:

• Standardize protocols thoroughly

• Include appropriate controls in each experiment

• Consider using multiple antibodies targeting different epitopes

• Carefully control experimental conditions, particularly calcium levels

How should researchers interpret changes in CAPN12 expression patterns?

Interpreting CAPN12 expression changes requires careful consideration:

• Context-specific analysis:

  • Compare with tissue or cell type-specific baseline expression

  • Consider expression patterns of other calpain family members

  • Correlate with calcium signaling pathways

• Functional correlation:

  • Determine if expression changes correlate with CAPN12 activity

  • Identify whether substrate cleavage patterns follow expression changes

  • Assess downstream cellular phenotypes

• Clinical relevance:

  • For patient samples, correlate with clinical parameters

  • Research indicates CAPN12 is overexpressed in pancreatic cancer and correlates with advanced cancer stages

  • Consider potential as a biomarker or therapeutic target

When analyzing CAPN12 expression, researchers should employ quantitative methods and appropriate statistical analysis to ensure robust interpretation of results.

What is known about CAPN12 expression in cancer?

Current research highlights several key findings about CAPN12 in cancer:

These findings position CAPN12 as a potential biomarker for cancer progression and possibly a therapeutic target, though more research is needed to fully establish its clinical utility.

How is CAPN12 connected to immune infiltration in tumors?

The relationship between CAPN12 and the tumor immune microenvironment is an emerging area:

• Analysis methodology:

  • Research has employed single-sample Gene Set Enrichment Analysis (ssGSEA) to explore relationships between calpains and immune cell infiltration

  • Spearman correlation tests have been used to assess these relationships

• Family patterns:

  • While specific data for CAPN12 is limited, other calpains show significant correlations with immune cell populations

  • CAPN1, 2, 5, and 8 correlate with tumor-infiltrating T follicular helper cells

  • CAPN10 correlates with tumor-infiltrating T helper 2 cells

• Potential mechanisms:

  • Calpains may influence immune cell recruitment or function through:

    • Modification of chemokines or cytokines

    • Alteration of extracellular matrix components

    • Regulation of immune response signaling pathways

Understanding CAPN12's specific role in immune infiltration could inform immunotherapy approaches and combination treatment strategies in cancer.

What methodologies are used to study CAPN12 in patient samples?

Several complementary approaches can be employed to study CAPN12 in clinical specimens:

• Protein detection methods:

  • Immunohistochemistry using CAPN12 antibodies on tissue sections

  • Western blotting of protein lysates from patient samples

  • Tissue microarrays for high-throughput analysis

• Transcriptomic analysis:

  • RNA sequencing or microarray analysis of tumor and normal tissues

  • Quantitative RT-PCR for targeted expression analysis

  • Single-cell RNA-seq to analyze expression in specific cell populations

• Bioinformatic approaches:

  • Analysis using databases like Oncomine, GEPIA, and Kaplan-Meier plotter

  • Correlation analysis with clinical parameters

  • Survival analysis using Kaplan-Meier methods and Cox regression

• Functional validation:

  • Ex vivo culture of patient-derived samples

  • Patient-derived xenograft models

  • Correlation of CAPN12 levels with treatment response

These multi-modal approaches provide comprehensive insights into CAPN12's role in disease and its potential utility as a biomarker or therapeutic target.